Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

The ‘Access to Medicines’ Debate: Throwing Patients Without Cures Under the Proverbial Bus

Access to Medicines

The vast majority of the world’s patients remain completely forgotten in the ‘access to medicines’ debate.   Many fail to understand how that elimination will affect the development of the cures and treatments of tomorrow, especially for rare diseases, cancers, and other serious unmet medical conditions. The Forgotten: 25 million Americans suffer from nearly 7000 rare diseases.  30 million European Union citizens suffer from between 6000 to 8000 rare diseases, 80% of which are of genetic origin Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

Biotech Patenting Event: BIO’s 2012 Fall IPCC in Charleston, South Carolina

charleston

BIO’s 2012 Fall IPCC Conference event on November 12-14 gathers biotech in-house counsels to provide and discuss relevant IP developments.  The Honorable Jimmie V. Reyna, Circuit Judge for the United States Court of Appeals for the Federal Circuit keynotes this year’s program along with the Honorable Judge Sally Gardner Lane, Administrative Patent Judge, Trial Division, Board of Patent Appeals and Interferences. Find program topics and speakers below.  Click here for the full agenda.   Picking the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

Finding Value in Early Stage Collaborations at the BIO Technology Transfer Symposium

Bridge

The BIO Technology Transfer Symposium dissects recent academia-industry collaborations and evaluates the value in early stage biotechnology investments.  The event occurs in San Francisco on October 8th ahead of the BIO Investor Forum and provides a unique opportunity for bringing academia, industry, and the investment community together. This year’s event is headlined by Tom Thornton from the Cleveland Clinic, a leading academic medical center.  The first panel highlights the collaboration between Duke Translational Research Institute Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO Voices Agree: Intellectual Property Delivers

Smethurst_Aaron

Over the last year, the U.S. Chamber of Commerce’s Global IP Center (GIPC) has met with entrepreneurs from around the world to get their personal stories on what it takes to become a breakthrough innovator in the 21st century. While the products that these innovators create come in many shapes and sizes, all of those we’ve come into contact with—many of whom from the annual BIO International Convention—have displayed a resounding respect for and interest Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Novartis at India Supreme Court: Evergreening Myths and Patent Reality

Pine

Novartis will go before India’s Supreme Court on September 11, 2012 challenging the refusal by the Indian Patent Office to grant a patent on its cancer drug Glivec.  The Indian Patent Office rejected Novartis’ application under a provision in Indian law which is aimed at guarding against so called “patent evergreening.” BIO has written two posts deconstructing the myth of patent evergreening. 1.  Patent “Ever-Greening”: Novartis Confronts Patent Myth in India 2.  Patent Evergreening in Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,